ClinicalTrials.gg
RecruitingNCT04307485Updated Oct 6, 2023

A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients

A Phase 4 interventional study of Ticagrelor in Senior Acute Coronary Syndrome Patients After PCI, sponsored by Shanghai Tong Ren Hospital. Recruiting at 1 site in China. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by Shanghai Tong Ren Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.

Planned enrollment
57th of 67
40 · median 120
Started
2020
with 3 others
Phase 4
38 of 67
5 open now
Registered
56th of 67
by date
Lead sponsor
3 of 67
Shanghai Tong Ren Hospital

Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 57th largest by planned enrollment, is one of 4 that started in 2020, is one of 38 in phase 4, and was the 56th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing ticagrelor in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

In this study, the investigates try to confirm our hypothesis that low dose ticagrelor(60mg) had similar anti-platelets function compared with the standard dose ticagrelor in senior (no less than 75 years old)acute coronary syndrome patients . Totally 40 senior ACS patients will be divided into 2 groups randomly one month after PCI . Group 1 will be treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group; Group 2 will be treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT treatment. The platelets function will be tested in VASP and TEG methods 2 months after PCI as the primary endpoints.The clinical events will be observed 12 months after PCI.

03

Conditions studied

  • Senior Acute Coronary Syndrome Patients After PCI
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.Subject must be at least 75 years of age 2 Patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for acute coronary syndrome 3.Subject understand the study requirements and the treatment procedures and provided before the procedure

Exclusion criteria

Exclusion Criteria:

  1. Female of , unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
  2. Active bleeding
  3. Known or to study medications
  4. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
  5. Non-cardiac co-morbid conditions are present with \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment).
  6. Subjects with Cerebral hemorrhage history
  7. Subjects with stroke history in half a year
  8. subjects with active malignant tumor
  9. subjects with whom oral anticoagulants are needed
  10. Other conditions which the investigators think not applicable to the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    standard dose ticargrelor based DAPT therapy

    treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group

    Drug: Ticagrelor

  • Experimental
    low dose ticargrelor based DAPT

    treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT treatment

    Drug: Ticagrelor

Interventions

  • 90mg ticargrelor based DAPT vs 60mg ticargrelor based DAPT

06

What researchers measure

Primary outcomes

  1. changes of PRI detected by VASP methods

    platelet reactivity index (PRI) detected by VASP (Vasodilator Stimulated

    Time frame: changes of PRI from baseline (4weeks after index PCI) to 8 and 12 weeks after index PCI

  2. changes of Maximum Amplitude (MA) detected by TEG

    Maximum Amplitude (MA) detected by TEG(Thromboelastography)

    Time frame: changes of MA from baseline (4weeks after index PCI) to 8 and 12 weeks after index PCI

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Jun 2024, 51 months after the start.

Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 51 months is above that.

Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2020
First posted
Mar 13, 2020
StartActual
Mar 10, 2020
Primary completionEst.
Jun 2024
CompletionEst.
Jul 2024
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04307485
Lead sponsor
Shanghai Tong Ren Hospital
Responsible party
Hou Lei (Clinical Professor, Shanghai Tong Ren Hospital) — Principal investigator
First posted
Mar 13, 2020
Start date
Mar 10, 2020
Primary completion
Jun 2024 (estimated)
Completion
Jul 2024 (estimated)
Last update
Oct 6, 2023

Study contacts

Lei Hou, Doctor
Contact
Dr_houlei@163.com
13564868096

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion